Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor

Scott Z. Fields, MD, Bayer Pharmaceuticals explains Oncogenic Signaling with Larotrectinib | LOXO-195 for Those Progressed on TRK-Inhibitor at ASCO 2018 Author: Annual-Meeting Added: 06/21/2018
Source: Oncology Tube - Category: Cancer & Oncology Source Type: podcasts